Overview

A mid-cap biopharma company had a preclinical gene therapy asset. RxC was asked to assess the competitive gene therapy landscape to see how the treatment landscape is expected to change and how best to develop the gene therapy program to gain regulatory approval.

Approach

RxC worked closely with the client team to:

• Develop a profile of the disease for which the gene therapy product was indicated by understanding key unmet needs, epidemiology, and the current standard of care.

• Complete a competitive assessment of other agents in development for this indication through secondary research sources.

• Conduct KOL (Key Opinion Leader) research to refine the competitive evaluation.

• Assess the best practices around developing gene therapy

• Develop a TPP (Target Product Profile) and preliminary value proposition.

Results

The client has utilized RxC's findings regarding the Target Product Profile (TPP) and preliminary value proposition to refine the clinical program further.